Mereo BioPharma Group
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Mereo BioPharma Group generated cash of -$21,132,000, which is more than the previous year. Cash used in financing activities reached the amount of $7,973,000 last year. Net change in cash is therefore -$10,761,000.
Cash Flow
| 2016 | -27.39M | 372.61K | 68.35M |
|---|---|---|---|
| 2017 | -32.14M | -3.74M | 33.74M |
| 2018 | -23.13M | 251.55K | -2.07M |
| 2019 | -45.93M | 43.29M | -5.71M |
| 2020 | -28.34M | 1.49M | 34.73M |
| 2021 | -5.23M | -421K | 77.65M |
| 2022 | -38.82M | 1.49M | -784K |
| 2023 | -21.13M | -419K | 7.97M |
MREO Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 68.18M | 94.29M | 23.46M | 16.34M | 25.04M | 50.04M | 53.57M | 12.24M |
Operating activities | ||||||||
Net income | -29.46M | -36.09M | 14.24M | -166.45M | -41.11M | -37.30M | -46.95M | -33.72M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.06M | 727K | 642K | 1.59M | 1.57M | 37.79K | 36.07K | 32.94K |
Stock-based compensation expense | 4.92M | 4.76M | 4.45M | 2.12M | 1.63M | 0 | 3.65M | 6.49M |
| Deferred income tax benefit | 4.92M | 4.76M | 4.45M | 2.12M | 1.63M | 0 | 3.65M | 6.49M |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 456K | 695K | -589K | 141K | -936K | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -1.26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -21.13M | -38.82M | -5.23M | -28.34M | -45.93M | -23.13M | -32.14M | -27.39M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | -2.5M | 0 |
Investments In Property Plant And Equipment | 0 | -10K | -535K | -16K | -21K | -35.53K | -2.29M | -3.46K |
Acquisitions Net | 0 | 0 | 0 | -354K | 10.07M | 0 | 0 | 0 |
Cash generated by investing activities | -419K | 1.49M | -421K | 1.49M | 43.29M | 251.55K | -3.74M | 372.61K |
Financing activities | ||||||||
Common Stock Issued | 11.60M | 0 | 78.53M | 20.13M | 0 | 273.06K | 20.27M | 67.88M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | -1.30M | -306.83K | 0 | 0 |
Repayments of term debt | -3.18M | -1.13M | -692K | -21.88M | -2.90M | 0 | 27.02M | 0 |
Cash used in financing activities | 7.97M | -784K | 77.65M | 34.73M | -5.71M | -2.07M | 33.74M | 68.35M |
Net Change In Cash | -10.76M | -37.96M | 70.82M | 7.12M | -8.69M | -25.00M | -3.53M | 41.32M |
Cash at end of period | 57.42M | 56.33M | 94.29M | 23.46M | 16.34M | 25.04M | 50.04M | 53.57M |
| Data source | Data source | Data source | Data source | Data source | Data source |